Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Touchlight Aquaculture is an animal health biotechnology company focused on developing DNA vaccines for aquaculture, particularly fish health. It was formed in 2020 as a joint venture between Touchlight Genetics and Stonehaven Incubate to apply Touchlight's synthetic Doggybone dbDNA technology to aquaculture. The company's approach aims to enable scalable, lower-cost production of DNA vaccines for infectious diseases affecting farmed fish, with early work described in salmon disease settings. Public information suggests it has remained a small private venture with limited disclosed pipeline detail and appears to have become an acquired or merged corporate-backed entity while continuing as a registered UK company. For biotech analysts, it is best understood as a niche animal-health platform play built around enzymatically produced synthetic DNA vaccine constructs rather than a broad human therapeutics developer.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Touchlight Aquaculture.